Ampio enrolls patients for inhalable COVID-19 Phase I trial
The immunotherapy-focused firm reports enrollment stands at 55% for its ongoing study exploring viability of Ampion as an inhalable COVID-19 treatment. Ampio Pharmaceuticals, a company specializing in immunology-based therapies for inflammatory conditions, has announced that its ongoing Phase I clinical trial in the US, exploring inhalation treatment of COVID-19 with Ampion (AP-014), is now 55% enrolled. The trial is looking at the impact of inhaled Ampion treatments in patients suffering respiratory distress as a result of COVID-19 infection. Inhaled Ampion specif...
Source: outsourcing-pharma.com